Amneal Pharmaceuticals Inc’s filing revealed that its Director Patel Gautam unloaded Company’s shares for reported $0.45 million on Jun 10 ’25. In the deal valued at $8.02 per share,56,426 shares were sold. As a result of this transaction, Patel Gautam now holds 1,704,050 shares worth roughly $13.82 million.
Then, Shah Nikita sold 49,140 shares, generating $372,481 in total proceeds. Upon selling the shares at $7.58, the Executive Vice President now owns 388,929 shares.
Before that, Shah Nikita bought 49,140 shares. Amneal Pharmaceuticals Inc shares valued at $368,550 were divested by the Officer at a price of $7.50 per share.
Goldman initiated its Amneal Pharmaceuticals Inc [AMRX] rating to a Buy in a research note published on June 06, 2025; the price target was $12. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in late February from “a Neutral” to “an Overweight”. JP Morgan also remained covering AMRX and has increased its forecast on September 06, 2024 with a “Neutral” recommendation from previously “an Underweight” rating.
Price Performance Review of AMRX
On Monday, Amneal Pharmaceuticals Inc [NASDAQ:AMRX] saw its stock jump 4.65% to $8.11. Over the last five days, the stock has gained 6.57%. Amneal Pharmaceuticals Inc shares have risen nearly 2.40% since the year began. Nevertheless, the stocks have risen 14.06% over the past one year. While a 52-week high of $9.48 was reached on 03/03/25, a 52-week low of $6.29 was recorded on 04/10/25.
Levels Of Support And Resistance For AMRX Stock
The 24-hour chart illustrates a support level at 7.87, which if violated will result in even more drops to 7.63. On the upside, there is a resistance level at 8.23. A further resistance level may holdings at 8.35.
